MetaCap

Adicet Bio (ACET) vs Marker Therapeutics (MRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Marker Therapeutics (MRKR) has outperformed Adicet Bio (ACET) over the past year, gaining 2.8% versus a loss of 77.8%. Over five years, MRKR leads with a -91.1% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $18.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%MRKR+2.83%
+116%+14%-87%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%MRKR-91.62%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus MRKR key metrics
MetricACETMRKR
Share price$2.14$1.09
Market cap$20.03M$18.17M
1-day change-13.01%-17.42%
YTD return-74.58%-26.85%
1-year return-77.78%+2.83%
5-year return-98.58%-91.14%
EPS (TTM)$-7.53$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.55M
Revenue growth (YoY)—-46.19%
Net income (latest FY)$-116.80M$-12.16M
Operating margin—-363.45%
Net margin—-342.96%
52-week high$11.15$2.46
52-week low$2.12$0.81
Distance from 52-week high-80.81%-55.69%
Analyst consensusstrong_buynone
Avg. price target upside+1527.57%+622.02%
Average volume271.05K711.96K
Shares outstanding9.36M16.67M
Employees1025
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRKR has outperformed ACET by 80.6 percentage points over the past year.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

ACET vs MRKR FAQ

Which is bigger, Adicet Bio or Marker Therapeutics?

Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.17M for Marker Therapeutics (MRKR).

Which stock has performed better over the past year, ACET or MRKR?

MRKR returned +2.83% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and Marker Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons